Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

January 22, 2026

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

January 8, 2026

Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

January 7, 2026

Asieris Pharmaceuticals Appoints Dr. Ningshu Liu as Chief Scientific Officer

January 3, 2026

Asieris’ APL-1202 Receives Health Canada’s Special Access Program Approval for Treatment of Free-Living Amoeba Infections

December 21, 2025

Asieris Announces Completion of CE Application Submission for Bladder Cancer Product APLD-2304, Received by Notified Body BSI Group

December 16, 2025

Asieris Received NMPA Approval for IND of APL-2401 to Initiate Phase I Clinical Study in Patients with FGFR2/3-Driven Advanced Solid Tumors

Technology Platform